<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3366">
  <stage>Registered</stage>
  <submitdate>17/11/2011</submitdate>
  <approvaldate>17/11/2011</approvaldate>
  <nctid>NCT01476163</nctid>
  <trial_identification>
    <studytitle>Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease</studytitle>
    <scientifictitle>Physician Initiated Expanded Access Request for Treatment Use of Migalastat Hydrochloride (AT1001), an Investigational Treatment for Individual Patients With Fabry Disease (AT1001-188)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>AT1001-188</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Fabry Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - migalastat HCl

Treatment: drugs: migalastat HCl
150 mg capsule taken every other day by mouth. An inactive reminder capsule may be provided to take on the days in between migalastat HCl

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>-  Confirmed GLA mutation predicted to be responsive migalastat in the human embryonic
             kidney (HEK-293) cell-based assay

          -  16-74 years of age

          -  Strong clinical indication for treatment of Fabry disease

          -  No other treatment option including either unsuitable for ERT or unable to access ERT

          -  Appropriate female and male contraception

          -  Willing to receive treatment with migalastat HCl via this program including having
             signed an authorization for sharing clinical data</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>74</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Estimated glomerular filtration rate (eGFR) or GFR &lt;30 mL/minute

          -  Scheduled for renal or other organ transplant or replacement therapy

          -  Receiving GLYSET® (miglitol), ZAVESCA® (miglustat) or enzyme replacement therapy
             FABRAZYME® (agalsidase beta) or REPLAGAL (agalsidase alpha)

          -  Contraindication to migalastat, i.e., sensitivity to other iminosugar such as
             miglustat, miglitol

          -  Treated with another investigational drug within 30 days of start of migalastat HCl
             treatment

          -  Unable to comply with study requirements or deemed otherwise unsuitable for study
             entry in the opinion of the investigator.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Expanded Access</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Available</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <postcode>3050 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amicus Therapeutics</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This program allows physicians to request permission from Amicus Therapeutics (Amicus) for
      treatment access to migalastat hydrochloride (HCl) for specific adult patients with Fabry
      disease. Treatment is open label for 6 months with renewal every 6 months.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01476163</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Monitor, Clinical Research</name>
      <address>Amicus Therapeutics</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Amicus Therapeutics Patient Advocacy</name>
      <address />
      <phone />
      <fax />
      <email>clinicaltrials@amicusrx.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>